A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors Harboring NTRK Fusion

Interventions

DRUG: Larotrectinib (Vitrakvi, BAY2757556)

Sponsor

Bayer